AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02136524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
Study NCT02136524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
Study NCT04714203 — intervention group
Intervention type: OTHER
Intervention: sarcopenia assessment
Description: evaluation of sarcopenia status
Study NCT04549805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography Coronary Angiography
Description: In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
Study NCT01397032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Description: Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
Study NCT01397032 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition
Description: Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
Study NCT04557371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum
Description: Participants will topically apply the serum to the face as per normal home use application in place of their current facial serum product.
Study NCT04557371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lotion
Description: Participants will topically apply lotion to the face as per normal home use application in place of their current facial lotion product.
Study NCT04557371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream
Description: Participants will topically apply cream to the face as per normal home use application in place of their current facial cream product.
Study NCT03329950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
Study NCT03329950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: CDX-301 will be injected once a day for five days before Cycles 1 and 2.
Study NCT03329950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab will be administered every 3 weeks.
Study NCT03329950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
Study NCT02406482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microfinance intervention (MF)
Description: Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
Study NCT02406482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV risk reduction (HIVRR)
Description: Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
Study NCT02406482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV risk reduction (HIVRR)
Description: Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
Study NCT00901160 — intervention group
Intervention type: PROCEDURE
Intervention: blood test
Description: Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
Study NCT04140292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Description: PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered.
Study NCT04140292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result
Study NCT03393741 — intervention group
Intervention type: DRUG
Intervention: Taxane
Description: Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Study NCT03393741 — intervention group
Intervention type: DRUG
Intervention: Vinorelbine
Description: Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Study NCT03393741 — intervention group
Intervention type: DRUG
Intervention: Ixabepilone
Description: Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Study NCT03393741 — intervention group
Intervention type: DRUG
Intervention: Eribulin
Description: Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Study NCT03393741 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemotherapy is used to treat various stages of breast cancer.
Study NCT03305822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT04471441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus Tab.
Description: After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/mL.
Study NCT03305822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT01494194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air Structuring Protein
Description: A novel food protein preparation
Study NCT01494194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sorbet
Description: Placebo sorbet for double blind placebo controlled food challenge
Study NCT03149185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology based cognitive behavioral stress management
Description: Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
Study NCT03149185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology based health promotion group-based attention matched control condition
Description: Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
Study NCT02637453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: Pulmonary vein isolation
Study NCT04471441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil Tab./Cap.
Description: Up to 1.5g BID(total 3g daily), PO
Study NCT03075488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuro
Description: spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
Study NCT03075488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cutaneous landmarks
Description: spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
Study NCT02313870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol propionate + Methotrexate
Description: daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
Study NCT02313870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clobetasol propionate alone
Description: daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
Study NCT03474848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT
Description: Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
Study NCT03474848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy (OT)
Description: Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
Study NCT04796103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose Prolotherapy
Description: In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
Study NCT04796103 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose Prolotherapy
Description: In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
Study NCT04796103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serum Physiological Group (placebo control group)
Description: In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
Study NCT02637453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI+6L
Description: After PVI, 6 ablation lines were added with an extension from pulmonary vein ostium at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
Study NCT04796103 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Serum Physiological Group (placebo control group)
Description: In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
Study NCT01901523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reporting of discrepancy to journal
Study NCT03241342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTx 024
Description: Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
Study NCT03241342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
Study NCT03445650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 1% Topical Dermal Cream (reproxalap)
Description: ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
Study NCT03445650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of ADX-102 Topical Dermal Cream
Description: Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
Study NCT03939884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MuscleCare Topical Product
Description: Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
Study NCT01284478 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone Implant
Description: Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
Study NCT03659773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immune biomarkers to evaluate vaccine response in HSCT recipients
Description: a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
Study NCT03939884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren Topical
Description: Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
Study NCT03939884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nivea, Topical Cream
Description: Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
Study NCT03732001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined Docetaxel
Description: Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
Study NCT03732001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
Study NCT01045512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvastatin
Description: 40-80mg once daily
Study NCT01719523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Study NCT00849810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
Study NCT00849810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: 5 - 20 mg daily, at a stable dose for 4 to 5 weeks
Study NCT02651727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine
Description: IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
Study NCT02651727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine
Description: IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
Study NCT03305419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 capsule
Description: GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
Study NCT03305419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
Study NCT03305419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
Study NCT03024333 — intervention group
Intervention type: OTHER
Description: Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
Study NCT00075946 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV
Study NCT00075946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT03208907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CQ coadministered with PQ
Description: 113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
Study NCT03208907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PQP coadministered with PQ
Description: In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
Study NCT02651727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A- VS-4718, nab-paclitaxel, gemcitabine
Description: Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.